Mercer Global Advisors’s Generate Biomedicines GENB Stock Holding History

Mercer Global Advisors’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.53K	Buy	+150	New	+$2.04K	﹤0.01%	5538

Other funds holding GENB

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCP

Davern Capital Partners Ny, New York $587M AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Mercer Global Advisors's GENB Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Generate Biomedicines (GENB) in Q2 2026: 150 shares worth $2.53K. The stake represents ﹤0.01% of the portfolio and ranks #5538 among its holdings.

51 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Mercer Global Advisors held 150 shares of Generate Biomedicines worth $2.53K as of Q2 2026.
Generate Biomedicines was a new Mercer Global Advisors position in Q2 2026.
Generate Biomedicines made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5538 holding.
51 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.